Eculizumab in patients with classic PNH: A cost effectivity study.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON29026

Enrollment

Registered

2011-12-22

Start date

2011-11-01

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patient satisfaction, cost effectiveness, Qualtity of life, home-based treatment

Interventions

A questionnaire is filled in by patients. No intervention will be given because the patients are already using eculizumab.

Eligibility

Inclusion criteria

Inclusion criteria: 1. PNH patients treated with eculizumab; 2. Aged >= 18 years; 3. Informed consent.

Exclusion criteria

Exclusion criteria: No informed consent.

Design outcomes

Primary

Measure	Time frame
Satisfaction of patients (home care versus intramural administration) determined by a treatment satisfaction questionnaire.	—

Secondary

Measure	Time frame
1. Quality of life (EORTC and Facit Fatigue scale); 2. Resource utilisation; 3. Indirect costs (productivity losses); 4. Utility assessments (EQ-5D); 5. Clinical outcomes: safety and sustained reduction of hemolysis; 6. Quality control.	—

Contacts

Public ContactM. Reen, van

RUNMC, dep of Hematology

m.vanreen@hemat.umcn.nl+31 (0)31 243614794

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)